Limits...
Inhibition of baicalin on metabolism of phenacetin, a probe of CYP1A2, in human liver microsomes and in rats.

Gao N, Qi B, Liu FJ, Fang Y, Zhou J, Jia LJ, Qiao HL - PLoS ONE (2014)

Bottom Line: The genotypes of -3860G>A and -163C>A had no significant effect on the inhibition of baicalin on CYP1A2.The animal experiment results showed that baicalin (450 mg/kg, i.v.) significantly decreased the Cmax and CL of phenacetin, and increased C(60 min), t1/2, Vd and AUC (P<0.05).In conclusion, baicalin can inhibit the activity of CYP1A2 in HLMs and exhibit large inter-individual variation that has no relationship with gene polymorphism.

View Article: PubMed Central - PubMed

Affiliation: Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, People's Republic of China.

ABSTRACT
Baicalin has been used as mainly bioactive constituent of about 100 kinds of traditional Chinese medicines in Chinese pharmacopoeia. The effect of baicalin on cytochrome P450 should be paid more attention because baicalin was used widely. The aim of this study was to investigate whether baicalin could inhibit CYP1A2 in pooled human liver microsomes (HLMs) and in rats in vivo and the gene polymorphisms could affect inter-individual variation in IC50 in 28 human livers. Phenacetin was used as probe of CYP1A2. Kinetic parameter of CYP1A2 and IC50 of baicalin on CYP1A2 to each sample were measured and the common CYP1A2 polymorphisms (-3860G>A and -163C>A) were genotyped. The results showed that baicalin exhibited a mixed-type inhibition in pooled HLMs, with a Ki value of 25.4 µM. There was substantial variation in Km, Vmax, CLint of CYP1A2 and IC50 of baicalin on CYP1A2 (3∼10-fold). The range was from 26.6 to 114.8 µM for Km, from 333 to 1330 pmol·min(-1)·mg(-1)protein for Vmax and from 3.8 to 45.3 µL·min(-1)·mg(-1) protein for CLint in HLMs (n = 28). The Mean (range) value of IC50 in 28 HLMs was 36.3 (18.9 to 56.1) µM. The genotypes of -3860G>A and -163C>A had no significant effect on the inhibition of baicalin on CYP1A2. The animal experiment results showed that baicalin (450 mg/kg, i.v.) significantly decreased the Cmax and CL of phenacetin, and increased C(60 min), t1/2, Vd and AUC (P<0.05). There were significant correlations between percentage of control in C(60 min), t1/2, CL, AUC of phenacetin and Cmax of baicalin in 11 rats (P<0.05). Protein binding experiments in vitro showed that baicalin (0-2000 mg/L) increased the unbound phenacetin from 14.5% to 28.3%. In conclusion, baicalin can inhibit the activity of CYP1A2 in HLMs and exhibit large inter-individual variation that has no relationship with gene polymorphism. Baicalin can change the pharmacokinetics of phenacetin in rats.

Show MeSH
Plots of percentage of control in pharmacokinetic parameters of phenacetin versus Cmax of baicalin.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3935934&req=5

pone-0089752-g004: Plots of percentage of control in pharmacokinetic parameters of phenacetin versus Cmax of baicalin.

Mentions: Correlations of the changes in phenacetin pharmacokinetic parameters and baicalin: The study was a randomized, two-period crossover design, so the changes in pharmacokinetic parameters of each rat could be calculated. There were significantly differences in Cmax, C60 min, t1/2, Vd, CL and AUC of phenacetin between rats treated with normal saline and baicalin, so the correlations of this change (%) in parameters and Cmax or AUC of baicalin could be analyzed. The results showed that except Cmax and Vd, there were significant correlations between percentage of control in other pharmacokinetic parameters of phenacetin and Cmax of baicalin in 11 rats (P<0.05, Figure 4). In addition, there were no significant correlations between percentage of control in all pharmacokinetic parameters of phenacetin and AUC of baicalin (Figure 5).


Inhibition of baicalin on metabolism of phenacetin, a probe of CYP1A2, in human liver microsomes and in rats.

Gao N, Qi B, Liu FJ, Fang Y, Zhou J, Jia LJ, Qiao HL - PLoS ONE (2014)

Plots of percentage of control in pharmacokinetic parameters of phenacetin versus Cmax of baicalin.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3935934&req=5

pone-0089752-g004: Plots of percentage of control in pharmacokinetic parameters of phenacetin versus Cmax of baicalin.
Mentions: Correlations of the changes in phenacetin pharmacokinetic parameters and baicalin: The study was a randomized, two-period crossover design, so the changes in pharmacokinetic parameters of each rat could be calculated. There were significantly differences in Cmax, C60 min, t1/2, Vd, CL and AUC of phenacetin between rats treated with normal saline and baicalin, so the correlations of this change (%) in parameters and Cmax or AUC of baicalin could be analyzed. The results showed that except Cmax and Vd, there were significant correlations between percentage of control in other pharmacokinetic parameters of phenacetin and Cmax of baicalin in 11 rats (P<0.05, Figure 4). In addition, there were no significant correlations between percentage of control in all pharmacokinetic parameters of phenacetin and AUC of baicalin (Figure 5).

Bottom Line: The genotypes of -3860G>A and -163C>A had no significant effect on the inhibition of baicalin on CYP1A2.The animal experiment results showed that baicalin (450 mg/kg, i.v.) significantly decreased the Cmax and CL of phenacetin, and increased C(60 min), t1/2, Vd and AUC (P<0.05).In conclusion, baicalin can inhibit the activity of CYP1A2 in HLMs and exhibit large inter-individual variation that has no relationship with gene polymorphism.

View Article: PubMed Central - PubMed

Affiliation: Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, People's Republic of China.

ABSTRACT
Baicalin has been used as mainly bioactive constituent of about 100 kinds of traditional Chinese medicines in Chinese pharmacopoeia. The effect of baicalin on cytochrome P450 should be paid more attention because baicalin was used widely. The aim of this study was to investigate whether baicalin could inhibit CYP1A2 in pooled human liver microsomes (HLMs) and in rats in vivo and the gene polymorphisms could affect inter-individual variation in IC50 in 28 human livers. Phenacetin was used as probe of CYP1A2. Kinetic parameter of CYP1A2 and IC50 of baicalin on CYP1A2 to each sample were measured and the common CYP1A2 polymorphisms (-3860G>A and -163C>A) were genotyped. The results showed that baicalin exhibited a mixed-type inhibition in pooled HLMs, with a Ki value of 25.4 µM. There was substantial variation in Km, Vmax, CLint of CYP1A2 and IC50 of baicalin on CYP1A2 (3∼10-fold). The range was from 26.6 to 114.8 µM for Km, from 333 to 1330 pmol·min(-1)·mg(-1)protein for Vmax and from 3.8 to 45.3 µL·min(-1)·mg(-1) protein for CLint in HLMs (n = 28). The Mean (range) value of IC50 in 28 HLMs was 36.3 (18.9 to 56.1) µM. The genotypes of -3860G>A and -163C>A had no significant effect on the inhibition of baicalin on CYP1A2. The animal experiment results showed that baicalin (450 mg/kg, i.v.) significantly decreased the Cmax and CL of phenacetin, and increased C(60 min), t1/2, Vd and AUC (P<0.05). There were significant correlations between percentage of control in C(60 min), t1/2, CL, AUC of phenacetin and Cmax of baicalin in 11 rats (P<0.05). Protein binding experiments in vitro showed that baicalin (0-2000 mg/L) increased the unbound phenacetin from 14.5% to 28.3%. In conclusion, baicalin can inhibit the activity of CYP1A2 in HLMs and exhibit large inter-individual variation that has no relationship with gene polymorphism. Baicalin can change the pharmacokinetics of phenacetin in rats.

Show MeSH